TopiqIL Platform

Avro’s TopiqIL platform technology utilizes biocompatible ionic liquid pairs, derived from some of the human body’s natural building blocks, to facilitate lipid extraction in the stratum corneum and epidermis, which serve as the largest barrier to dermal delivery.

In contrast to conventional permeation enhancers, which work on the principles of lipid fluidization, our tech extracts lipids from the skin and washes them out, replacing the lipid content with our novel IL formulation and water, forming a non-toxic and safe depot of the payload deep within the skin’s layers. Our ionic liquid combinations allow for the encapsulation and where relevant, complexation, of a variety of payloads for localized or intracellular delivery into the skin.

Currently, there is no effective way to deliver the next generation of nucleic acid therapeutics into the skin, in a safe and patient-compliant manner. Dermatology clinical trials in these areas require costly and complex procedures such as diseased skin biopsies, cell culturing, skin grafts, injections, dermarolling, and skin pre-treatment that is often impossible in application due to the features of the rare disease states being treated. Furthermore, it’s currently impossible to deliver a nucleic acid therapy targeted to the skin systemically, in the same way as one might deliver a protein or antibody intravenously.

Countless next-generation dermal therapies under development are left without an enabling vehicle to reach patients. Avro’s technology solves this, delivering these large, charged, and complex molecules through the skin, directly to the site of action. Our team is developing proof of concepts across a number of therapeutic modalities including:

Currently only delivered systemically with widespread side effects and inefficient distribution to the site of action, ie. localized anti-TNFα activity through dermal etanercept delivery
Currently requires an extensive process involving biopsies of diseased host skin followed by culturing, transfection and grafting of healthy skin grafts, ie. exon skipping for the treatment of epidermolysis bullosa; no dermal therapies approved to date
Currently requires microneedles & electroporation or intradermal injections in the case of self-delivering siRNAs, impossible to deliver to epidermal cells and keratinocytes otherwise, ie. siRNAs for nucleotide change/deletion for the treatment pachyonychia congenita. No dermal therapies approved to date.
Currently in its infancy as a therapeutic modality, and has demonstrated massive potential in transcript replacement, and genome editing, ie. expression of connective tissue growth factor to treat skin fibrosis, or correction of RDEB fibroblasts. No dermal therapies approved to date.
Currently requires dermarolling, microneedles, or intradermal injections upon damaged skin. Widespread topical administration is key to effective targeted therapy and lasting treatment, ie. homology directed repair of TGM1 for ARCI. No dermal therapies approved to date.